Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.

Chadha MK, Lombardo J, Mashtare T, Wilding GE, Litwin A, Raczyk C, Gibbs JF, Kuvshinoff B, Javle MM, Iyer RV.

Anticancer Res. 2009 Oct;29(10):4127-30.

2.

Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.

Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D.

World J Gastroenterol. 2015 Feb 14;21(6):1945-55. doi: 10.3748/wjg.v21.i6.1945. Review.

3.

Octreotide LAR: safety and tolerability issues.

Bornschein J, Drozdov I, Malfertheiner P.

Expert Opin Drug Saf. 2009 Nov;8(6):755-68. Review.

PMID:
19998528
4.

Somatostatin analog octreotide LAR in gastro-entero-pancreatic tumors.

Oberg K.

Expert Rev Anticancer Ther. 2009 May;9(5):557-66. doi: 10.1586/era.09.26. Review.

PMID:
19445573
5.

[Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].

Simonenko VB, Dulin PA, Makanin MA.

Klin Med (Mosk). 2006;84(4):4-8. Review. Russian.

PMID:
16755846
6.

[Somatostatin analogues for the treatment of gastro-entero-pancreatic neuroendocrine tumours].

Uomo G, Germano D, Rabitti PG.

Minerva Endocrinol. 2001 Dec;26(4):225-9. Review. Italian.

PMID:
11782707
7.

Cytotoxic therapy of gastroenteropancreatic (GEP) tumors.

Syrigos KN, Sitara D, Georgiou E, Harrington KJ.

Anticancer Res. 2002 Mar-Apr;22(2B):1311-4. Review.

PMID:
12168943
8.

Interferon in the management of neuroendocrine GEP-tumors: a review.

Oberg K.

Digestion. 2000;62 Suppl 1:92-7. Review.

PMID:
10940694
9.

Molecular genetics of gastroenteropancreatic neuroendocrine tumors.

Starker LF, Carling T.

Curr Opin Oncol. 2009 Jan;21(1):29-33. doi: 10.1097/CCO.0b013e328319ea7b. Review.

PMID:
19125015
10.

Octreotide LAR for the treatment of acromegaly.

Vallette S, Serri O.

Expert Opin Drug Metab Toxicol. 2008 Jun;4(6):783-93. doi: 10.1517/17425255.4.6.783 . Review.

PMID:
18611118
11.

The epidemiology of gastroenteropancreatic neuroendocrine tumors.

Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM.

Endocrinol Metab Clin North Am. 2011 Mar;40(1):1-18, vii. doi: 10.1016/j.ecl.2010.12.005. Review.

PMID:
21349409
12.
13.

Update on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging.

Kim KW, Krajewski KM, Nishino M, Jagannathan JP, Shinagare AB, Tirumani SH, Ramaiya NH.

AJR Am J Roentgenol. 2013 Oct;201(4):811-24. doi: 10.2214/AJR.12.10240. Review.

14.

A review of the current clinical trials for gastroenteropancreatic neuroendocrine tumours.

Strosberg JR, Kvols LK.

Expert Opin Investig Drugs. 2007 Feb;16(2):219-24. Review.

PMID:
17243941
15.

Peptide receptor expression in GEP-NET.

Reubi JC.

Virchows Arch. 2007 Aug;451 Suppl 1:S47-50. Epub 2007 Aug 8. Review.

PMID:
17684767
16.

Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors.

Klöppel G, Rindi G, Anlauf M, Perren A, Komminoth P.

Virchows Arch. 2007 Aug;451 Suppl 1:S9-27. Epub 2007 Aug 8. Review.

PMID:
17684761
17.
18.

Gastroenteropancreatic neuroendocrine tumors in children and young adults.

Khanna G, O'Dorisio SM, Menda Y, Kirby P, Kao S, Sato Y.

Pediatr Radiol. 2008 Mar;38(3):251-9, quiz 358-9. Epub 2007 Sep 29. Review.

19.

Established and potential therapeutic applications of octreotide in palliative care.

Prommer EE.

Support Care Cancer. 2008 Oct;16(10):1117-23. doi: 10.1007/s00520-007-0399-4. Epub 2008 Feb 7. Review.

PMID:
18256859
20.

Hereditary neuroendocrine tumors of the gastroenteropancreatic system.

Anlauf M, Garbrecht N, Bauersfeld J, Schmitt A, Henopp T, Komminoth P, Heitz PU, Perren A, Klöppel G.

Virchows Arch. 2007 Aug;451 Suppl 1:S29-38. Epub 2007 Aug 8. Review.

PMID:
17684762

Supplemental Content

Support Center